TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06242912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QOL - quality of life
Description: QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiographic or laboratory evaluation
Description: Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
Study: NCT06335082

Intervention type: DEVICE
Intervention: Pulsed Field Ablation
Description: Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)

Intervention type: DEVICE
Intervention: Pulsed Field Ablation
Description: Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)

Intervention type: DEVICE
Intervention: Pulsed Field Ablation
Description: Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)
Study: NCT05996198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Rift headset
Description: The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Rift headset
Description: The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Device
Description: The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Device
Description: The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
Study: NCT06012435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
Study: NCT06119464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: Education
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: Audit and Feedback
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: Patient Engagement
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: System Changes
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
Study: NCT04831580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci
Description: Minimally invasive robotic-assisted radical or simple hysterectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: open radical or simple hysterectomy
Study: NCT06641310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Therapy
Description: * Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study.
Study: NCT05686395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Interscalene Block group
Description: ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
Description: Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine 0.25%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine 0.25%.
Study: NCT04100135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actual device PFO closure
Description: Actual PFO closure with the GORE® CARDIOFORM Septal Occluder

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thienopyridine (clopidogrel or prasugrel)
Description: Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine (clopidogrel or prasugrel)
Description: Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Study: NCT06030453

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SMART HOME strategy
Description: Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PADIS nursing intervention
Description: pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
Study: NCT05479994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally
Study: NCT03813095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1501
Description: The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1501
Description: The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
Study: NCT04100135

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device PFO closure
Description: Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
Study: NCT03813095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1501
Description: The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
Study: NCT06450041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal Donor (UD) TGFβi NK Cells
Description: Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
Study: NCT05863247

Intervention type: OTHER
Intervention: Patient Reported Outcomes / Biometric data revision
Description: Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
Study: NCT06450041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/dose IV daily on days 1-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: 17.5mg/m2/dose IV daily on days 2-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
Study: NCT05864807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCon
Description: The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
Study: NCT04898647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fundoscopic picture
Description: A central review of numerised fundoscopic picture will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fundoscopic picture
Description: A central review of numerised fundoscopic picture will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fundoscopic picture
Description: A central review of numerised fundoscopic picture will be performed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow sample
Description: Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow sample
Description: Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow sample
Description: Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
Study: NCT05332002

Intervention type: DRUG
Group type: OTHER
Intervention: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Description: This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).~The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:~1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:~2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2~3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric
Study: NCT05183191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving with a driving simulator
Description: Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
Study: NCT04596670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-ICAM-1pep
Description: 68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-ICAM-1pep
Description: 68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Study: NCT06411847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual appointments
Description: This group will receive the same information as the control group with additional virtual appointments at 1 week, 2 weeks and 6 weeks after fitting a Twin Block appliance. These will be scheduled and held via BlueEye Clinic (RedZinc Services Ltd.), a web-based GDPR compliant platform that allows patients to access a remote video consultation via a link sent to the participant/parent's device. The content of these appointments will follow a template that addresses the patient's experience, difficulties faced and how to overcome these, and would incorporate use of visual aids to highlight expected changes over the duration of wear. The appointments would be held in the late afternoons (after school).
Study: NCT05734677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation group
Description: 90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
Study: NCT05909085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ultrasound
Description: Labor epidural will be performed after marking patient skin using traditional ultrasound guidance

Intervention type: DEVICE
Group type: OTHER
Intervention: Automated ultrasound
Description: Labor epidural will be performed after marking patient skin using an automated ultrasound device
Study: NCT05278221

Intervention type: DEVICE
Group type: OTHER
Intervention: Software EstimLT
Description: Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested

Intervention type: DEVICE
Group type: OTHER
Intervention: Software EstimLT
Description: Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
Study: NCT05066217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemizole HCl
Description: Double-Blind Randomized

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match EPX-100
Description: Double-Blind Randomized
Study: NCT05487989

Intervention type: OTHER
Intervention: Clinical examen
Description: MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
Study: NCT06208215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC
Description: Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RZ358 (10 mg/kg) or Placebo + SOC
Description: Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 (5-10 mg/kg) + SOC
Description: Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
Study: NCT06558370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Empty bladder group
Description: Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder distension group
Description: Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
Study: NCT05248711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Daily Move
Description: The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
Study: NCT04883983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Placebo
Description: Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient medication as standardly prescribed
Description: Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
Study: NCT06177808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-compliant balloon
Description: As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
Study: NCT05056831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend face-to-face mind-body sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive targeted text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06498037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Administration of subcutaneously administered fentanyl loading boluses
Study: NCT05813470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab (CinnaGen)
Description: Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
Description: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
Study: NCT05435430

Intervention type: OTHER
Intervention: PERSPECTIVE, MULTICENTRIC and observational
Description: we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.